Evidence map›Paper›PMID 41821001›Full record

ArticleParticle and fibre toxicology2026

A quantitative definition for poorly soluble particles.

Lan Ma-Hock, Heidi Stratmann, Matthias Hufnagel, Anthony M Bowden, Blanca Serrano Ramón, David Warheit, Rüdiger Battersby, Shannon M Krieger, Marco Kellert, Nils Krueger and 3 more

Abstract read
In one paragraph

Article in Particle and fibre toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Readiness of theFrontiers in toxicology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lan Ma-Hock *Experimental Toxicology and Ecology BASF SE, Carl-Bosch-Strasse 38, 67056, Ludwigshafen, Germany. Lan.ma-hock@basf.com.
Heidi Stratmann *Colors&Effects Switzerland AG, Efringerstrasse 32, Basel, 4057, Switzerland.
Matthias Hufnagel *Engelhard Arzneimittel GmbH & Co. KG, Herzbergstrasse 3, 61138, Niederdorfelden, Germany.
Anthony M BowdenSafety, Environmental & Regulatory Science, Unilever, Colworth Science Park, Bedfordshire, Sharnbrook, MK44 1LQ, UK.
Blanca Serrano RamónEuropean Centre for Ecotoxicology and Toxicology of Chemicals, Rue Belliard 40, Brussels, 1040, Belgium.
David WarheitWarheit Scientific LLC, Wilmington, USA.
Rüdiger BattersbyEBRC Consulting, Hannover, Germany.
Shannon M KriegerDow, Inc., Midland, USA.
Marco KellertWacker Chemie AG, Burghausen, Germany.
Nils KruegerEvonik Industries AG, Hanau-Wolfgang, Germany.
Bennard van RavenzwaayEnvironmental Science Consulting, Altrip, Germany.
Robert LandsiedelExperimental Toxicology and Ecology BASF SE, Carl-Bosch-Strasse 38, 67056, Ludwigshafen, Germany.
Helmut GreimTechnical University of Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poorly soluble low toxicity particles (PSLT) have long been a concept in particle toxicology and regulatory frameworks addressing inhalation hazards. The term PSLT refers to particles that exhibit low toxicity and minimal solubility in biological fluids, leading to prolonged retention in the lungs and potential overload effects. Historically, PSLT has been used to distinguish materials whose adverse effects are primarily driven by particle burden rather than intrinsic chemical toxicity. While the "low toxicity" (LT) component of the definition has been examined to a certain degree (Driscoll and Borm in Inhal Toxicol 32(2):53-62, 2020), the poorly soluble (PS)-criterion does not yet have a precise definition although it is critically influencing the interpretation of toxicological inhalation repeated dose studies and hazard classifications. An ECETOC Task Force (TF) was formed to define criteria for "poorly soluble" particles (PSPs). This paper presents a quantitative non-animal approach for defining PSP using a model particle, with a focus on its potential to cause volumetric lung overload and affect macrophage clearance mechanisms. The analysis allows to calculate a dissolution rate that would lead to a lung burden of about 1 µL/g of lung tissue (lung overload threshold according to Morrow (Morrow in Fundam Appl Toxicol 10(3):369, 1988)). Below this threshold dissolution rate, this specific model particle would qualify as PSP. In addition, a formula was presented to translate abiotic dissolution rates into biotic (rat) dissolution rates to allow a PS-assessment in an animal-free system. As proof of concept, the TF collected existing in vivo data from member companies, publicly available literature of presumed PS-substances, and reference materials. The collected data revealed that most substances exhibited dissolution rates below the critical threshold and that the lung burden at no observed adverse effect concentrations (NOAECs) remained below the lung overload limit. Importantly, this threshold dissolution rate can differ from particle to particle, depending on factors such as agglomerate density, particle size distribution, and expected concentration. Thus, it should be evaluated on a case-by-case basis.

Indexed as

Inhalation ExposureLungParticulate MatterAnimalsHumansParticle SizeSolubilityParticulate MatterClearance (max 7)DissolutionECETOCInflammationLung burdenPoorly soluble particle

Identifiers

PMID41821001
PMCPMC12983584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.